Loading stock data…
Prime Medicine (PRME)
$3.72+0.29 (+8.45%)
Market ClosedLast close Jun 29
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prime Medicine, Inc. in the Healthcare sector is trading at $3.72 with a market capitalization of $516M. Wall Street consensus targets $7.02 (10 analysts), implying a +88.6% move over the next 12 months. The stock is currently 46% below its 52-week high of $6.94, remaining 5.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +88.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $856,000↑ | $838,000↓ | $1.23M↑ | $1.11M↓ | $1.45M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.65M↓ | -$48.61M↑ | -$53.97M↓ | -$53.38M↓ | -$52.39M |
| Net Income | -$49.12M↓ | -$46.08M↑ | -$50.58M↑ | -$52.59M↓ | -$51.89M |
Peer Comparison
JNJUNHPFE
Fundamentals
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulom...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$515.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-258.64%
Volume
Today's trading volume
5.25M
Recent News
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs.
We're Keeping An Eye On Prime Medicine's (NASDAQ:PRME) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Prime Medicine...
Prime Medicine (PRME) Reports Q1 EPS
Prime Medicine, Inc. (NASDAQ:PRME) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 7, 2026, Prime Medicine, Inc. (NASDAQ:PRME) reported Q1 EPS of (28c), versus the consensus estimate of (25c). Revenue totaled $856,000, versus the consensus estimate of $844,220. Chief Executive Officer Allan Reine said that the company continues […]
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -15.99% and -45.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.